1. Scrip

SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

Nirogacestat Also In Anti-BCMA Combo, Ovarian Cancer Studies

 
• By Mandy Jackson

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

FDA approved written on translucent black space
SpringWorks will file for approval in Europe next year • Source: Shutterstock

SpringWorks Therapeutics Inc. will soon launch its first product after the US Food and Drug Administration approved the small molecule gamma secretase inhibitor Ogsiveo (nirogacestat) for adults with progressing desmoid tumors who require systemic treatment. As the first-ever drug approved to treat the rare tumors, Ogsiveo appears poised to enjoy a warm welcome from doctors and patients who have been searching for alternatives to often ineffective surgeries and off-label medicines.

Key Takeaways

  • The US FDA approved Ogsiveo on 27 November to treat adults with progressing desmoid tumors who require systemic treatment. The drug will be available within five...

Stamford, CT-based SpringWorks, which plans to make the drug available in the US within five to 10 days of its 27 November approval, set a wholesale acquisition cost (WAC) for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.